Try our Advanced Search for more refined results

Alexion Must Face Claims Of Stalling On Drug After Merger

By Bill Wichert (September 2, 2021, 8:45 PM EDT) -- A Delaware Chancery judge has ruled that former shareholders of a biopharmaceutical business acquired by Alexion Pharmaceuticals Inc. can continue going after the company for allegedly failing to make appropriate efforts in developing an autoimmune drug, nixing Alexion's bid to erase their breach of contract claim as premature....

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Attached Documents

Related Sections

Law Firms

Companies

Government Agencies

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!